Key Insights on Gross Profit: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.

Biotech Giants' Gross Profit Growth: 2014-2023

__timestampHalozyme Therapeutics, Inc.Lantheus Holdings, Inc.
Wednesday, January 1, 201452602000125519000
Thursday, January 1, 2015105812000135522000
Friday, January 1, 2016113485000137780000
Sunday, January 1, 2017285461000162135000
Monday, January 1, 2018141726000174885000
Tuesday, January 1, 2019150446000174811000
Wednesday, January 1, 2020224227000138761000
Friday, January 1, 2021361897000187695000
Saturday, January 1, 2022520812000581703000
Sunday, January 1, 2023636892000709543000
Monday, January 1, 2024855907000
Loading chart...

In pursuit of knowledge

A Decade of Growth: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.

In the ever-evolving landscape of biotechnology and pharmaceuticals, understanding financial performance is crucial. Over the past decade, Halozyme Therapeutics, Inc. and Lantheus Holdings, Inc. have demonstrated remarkable growth in gross profit, reflecting their strategic advancements and market adaptability.

From 2014 to 2023, Halozyme's gross profit surged by over 1,100%, starting from a modest $52.6 million to an impressive $636.9 million. Meanwhile, Lantheus Holdings experienced a similar trajectory, with a 465% increase, reaching $709.5 million in 2023. Notably, both companies saw significant jumps in 2022, with Lantheus surpassing Halozyme for the first time in this period.

This financial ascent underscores the dynamic nature of the industry, where innovation and strategic positioning can lead to substantial economic gains. As these companies continue to evolve, their financial narratives offer valuable insights into the broader market trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025